.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,236,907

« Back to Dashboard

Details for Patent: 5,236,907

Title: Ocular hypotensive agents
Abstract:The present invention relates to an ocular hypotensive treatment of glaucoma which comprising employing 20-substituted-PGs or 20-substituted15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Oda; Tomio (Sanda, JP)
Assignee: R-Tech Ueno Ltd. (Osaka, JP)
Filing Date:Oct 11, 1991
Application Number:07/774,750
Claims:1. A method for treating ocular hypertension in a patient needing such treating which comprises administering to said patient an amount of a prostaglandin effective to treat ocular hypertension, wherein the prostaglandin is represented by a formula (I):

(in which R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl); Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain Z is saturated or unsaturated C.sub.7 -C.sub.9 aliphatic hydrocarbon straight-chain; or a physiologically acceptable salt or esterified carboxyl group derivative selected from the group consisting of C.sub.1-8 alkyl, C.sub.3-6 cycloalkyl, benzyl, phenyl, hydroxy C.sub.1-3 alkyl, C.sub.1-2 alkoxy C.sub.1-3 alkyl, tri C.sub.1-2 alkylsilyl and tetrahydropyranyl.

2. The method of claim 1, wherein Z is represented by a formula (II):

(in which R.sub.2 is a C.sub.2-4 alkyl group).

3. The method of claim 2, wherein the R.sub.2 is an ethyl group.

4. A method for treating glaucoma in a patient needing such treating which comprises administering to said patient an amount of a prostaglandin effective to treat glaucoma, wherein the prostaglandin is represented by a formula (I): ##STR9## (in which R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl); Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain; Z is saturated or unsaturated C.sub.7-C.sub.9 aliphatic hydrocarbon straight-chain; or a physiologically acceptable salt or esterified carboxyl group derivative selected from the group consisting of C.sub.1-8 alkyl, C.sub.3-6 cycloalkyl, benzyl, phenyl, hydroxy C.sub.1-3 alkyl, C.sub.1-2 alkoxy C.sub.1-3 alkyl, tri C.sub.1-2 alkylsilyl and tetrahydropyranyl.

5. An ocular hypotensive composition comprising an amount of a prostaglandin effective as an ocular hypotensive agent and a pharmaceutically acceptable carrier, wherein the prostaglandin is represented by a formula (IV): ##STR10## wherein, A is (in which R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl); or a physiologically acceptable salt or a C.sub.1-4 alkyl ester.

6. The composition of claim 5, wherein A is ##STR11##

7. The composition of claim 6, wherein A is ##STR12## and the compound of formula (IV) is a C.sub.1-4 alkyl ester.

8. The composition of claim 7, wherein the C.sub.1-4 alkyl ester is the isopropyl ester.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc